ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Nov 2022
Historique:
revised: 23 06 2022
received: 12 02 2022
accepted: 27 06 2022
pubmed: 6 7 2022
medline: 8 11 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with dismal prognosis. Recently, molecular subtypes of SCLC have been defined by the expression status of ASCL1, NEUROD1, YAP1, and POU2F3 transcription regulators. ASCL1 is essential for neuroendocrine differentiation and is expressed in the majority of SCLC. Although previous studies investigated ASCL1 target genes in SCLC cells, ASCL1-mediated regulation of miRNAs and its relationship to molecular subtypes remain poorly explored. Here, we performed genome-wide profiling of chromatin modifications (H3K27me3, H3K4me3, and H3K27ac) by CUT&Tag assay and ASCL1 knockdown followed by RNA sequencing and miRNA array analyses in SCLC cells. ASCL1 could preferentially regulate genes associated with super-enhancers (SEs) defined by enrichment of H3K27ac marking. Moreover, ASCL1 positively regulated several SE-associated miRNAs, such as miR-7, miR-375, miR-200b-3p, and miR-429, leading to repression of their targets, whereas ASCL1 suppressed miR-455-3p, an abundant miRNA in other molecular subtypes. We further elucidated unique patterns of SE-associated miRNAs in different SCLC molecular subtypes, highlighting subtype-specific miRNA networks with functional relevance. Notably, we found apparent de-repression of common target genes of different miRNAs following ASCL1 knockdown, suggesting combinatorial action of multiple miRNAs underlying molecular heterogeneity of SCLC (e.g., co-targeting of YAP1 by miR-9 and miR-375). Our comprehensive analyses provide novel insights into SCLC pathogenesis and a clue to understanding subtype-dependent phenotypic differences.

Identifiants

pubmed: 35789143
doi: 10.1111/cas.15481
pmc: PMC9633298
doi:

Substances chimiques

MicroRNAs 0
Basic Helix-Loop-Helix Transcription Factors 0
ASCL1 protein, human 0
MIRN455 microRNA, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3932-3946

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 16H02653
Organisme : Japan Society for the Promotion of Science
ID : 18K08170
Organisme : Japan Society for the Promotion of Science
ID : 21K16111
Organisme : Takeda Science Foundation
ID : medical research grant

Informations de copyright

© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Sci Transl Med. 2013 May 22;5(186):186ra66
pubmed: 23698379
Brain Res. 2019 Feb 15;1705:75-94
pubmed: 29709504
Genome Res. 2019 Nov;29(11):1791-1804
pubmed: 31649056
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Thorac Oncol. 2018 Nov;13(11):1676-1691
pubmed: 30121393
Cancer Res. 2011 Oct 1;71(19):6165-73
pubmed: 21856745
Elife. 2015 Aug 12;4:
pubmed: 26267216
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Cancer Sci. 2016 Dec;107(12):1755-1766
pubmed: 27627196
Cell. 2017 Mar 9;168(6):1000-1014.e15
pubmed: 28283057
Cell Rep. 2020 Oct 20;33(3):108296
pubmed: 33086069
Cell. 2016 Jul 14;166(2):328-342
pubmed: 27374332
Cancer Cell. 2021 Mar 8;39(3):346-360.e7
pubmed: 33482121
Cancer Sci. 2021 Aug;112(8):2984-2992
pubmed: 34107132
Mol Cell. 2018 May 17;70(4):707-721.e7
pubmed: 29754823
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Cancer Sci. 2016 Oct;107(10):1527-1538
pubmed: 27418196
Cancer Cell. 2014 Dec 8;26(6):909-922
pubmed: 25490451
Cell Rep. 2016 Aug 2;16(5):1259-1272
pubmed: 27452466
Cancer Cell. 2017 Feb 13;31(2):270-285
pubmed: 28089889
Cancer Sci. 2021 Apr;112(4):1376-1382
pubmed: 33615636
Cell Rep. 2016 Jul 19;16(3):631-43
pubmed: 27373156
Epigenetics Chromatin. 2019 Jul 12;12(1):42
pubmed: 31300027
Mol Cancer Ther. 2015 Oct;14(10):2167-74
pubmed: 26253517
Cancer Sci. 2011 Jan;102(1):9-17
pubmed: 20735434
Nat Protoc. 2020 Oct;15(10):3264-3283
pubmed: 32913232
Cancer Sci. 2022 Feb;113(2):382-391
pubmed: 34865286
Cancer Sci. 2022 Nov;113(11):3932-3946
pubmed: 35789143
Oncogene. 2015 Jun 11;34(24):3085-94
pubmed: 25132266
Cell. 2013 Nov 7;155(4):934-47
pubmed: 24119843
Cancer Res. 2008 Mar 15;68(6):1647-55
pubmed: 18339843
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17764-17774
pubmed: 32661162
Genes Dev. 2018 Jul 1;32(13-14):915-928
pubmed: 29945888
Diagnostics (Basel). 2020 Nov 13;10(11):
pubmed: 33202998
J Thorac Oncol. 2014 Sep;9(9):1324-31
pubmed: 25122428
J Thorac Oncol. 2020 Dec;15(12):1823-1835
pubmed: 33011388
Nat Rev Cancer. 2017 Dec;17(12):725-737
pubmed: 29077690
J Pathol. 2018 Oct;246(2):154-165
pubmed: 29876935
Am J Pathol. 2015 Dec;185(12):3164-77
pubmed: 26482608
FEBS J. 2016 May;283(10):1812-22
pubmed: 26663363
Cell. 2013 Apr 11;153(2):307-19
pubmed: 23582322
Bioinformatics. 2009 Aug 1;25(15):1952-8
pubmed: 19505939
PLoS One. 2015 Dec 07;10(12):e0144187
pubmed: 26642205
J Thorac Oncol. 2021 Mar;16(3):464-476
pubmed: 33248321
Int J Cancer. 2016 Feb 15;138(4):927-38
pubmed: 26340530
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Nat Rev Clin Oncol. 2017 Sep;14(9):549-561
pubmed: 28534531
Cancer Cell. 2020 Jul 13;38(1):60-78.e12
pubmed: 32473656
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Cancer Res. 2005 Dec 1;65(23):10680-5
pubmed: 16322211
J Natl Cancer Inst. 2016 May 31;108(10):
pubmed: 27247353
iScience. 2021 Aug 05;24(9):102953
pubmed: 34466783
Oncotarget. 2016 Nov 22;7(47):77378-77388
pubmed: 27764802
Nat Commun. 2019 Apr 29;10(1):1930
pubmed: 31036827
Sci Rep. 2013;3:1911
pubmed: 23714854
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14788-93
pubmed: 25267614
J Thorac Oncol. 2020 Apr;15(4):520-540
pubmed: 32018053
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Cancer Lett. 2004 Feb 20;204(2):159-69
pubmed: 15013215

Auteurs

Kazuko Miyakawa (K)

Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Naoya Miyashita (N)

Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Masafumi Horie (M)

Department of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.

Yasuhiro Terasaki (Y)

Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.

Hidenori Tanaka (H)

Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Hirokazu Urushiyama (H)

Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Kensuke Fukuda (K)

Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Yugo Okabe (Y)

Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Takashi Ishii (T)

Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Division for Health Service Promotion, The University of Tokyo, Tokyo, Japan.

Naomi Kuwahara (N)

Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.

Hiroshi I Suzuki (HI)

Division of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Institute for Glyco-core Research (iGCORE), Nagoya University, Nagoya, Japan.

Takahide Nagase (T)

Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Akira Saito (A)

Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH